Engineered Exosomes Combat Glioblastoma by Modulating Gut Microbiome and Inducing Cell Death

Glioblastoma Multiforme (GBM) is an aggressive and highly lethal brain cancer with a dismal prognosis, often resistant to conventional therapies. Growing evidence suggests a significant link between gut dysbiosis (an imbalance in gut microbiota) and cancer progression, including its impact on GBM. Current treatment strategies often lack the ability to simultaneously target the tumor directly and address systemic factors like the microbiome, leaving a critical gap in therapeutic options; this study specifically addresses how engineered exosomes can simultaneously block gut dysbiosis and induce GBM cell death.

The engineered exosomes demonstrated significant anti-tumor effects in vitro, reducing GBM cell viability by 62% (p<0.001) compared to untreated controls and inducing apoptosis (programmed cell death) in 38% of cells. In vivo, treatment with engineered exosomes led to a notable reduction in tumor volume, with treated mice showing 42% smaller tumors than control groups (p<0.05) after two weeks of treatment. This dual action suggests a synergistic therapeutic effect, where the exosomes directly target cancer cells while simultaneously mitigating gut dysbiosis, which can influence tumor progression and treatment response. Furthermore, the study revealed a significant modulation of the gut microbiome, with the exosome treatment restoring a healthier microbial balance, characterized by a 2.5-fold increase in beneficial bacteria (e.g., Lactobacillus) and a 1.8-fold decrease in pro-inflammatory species.